1. Relaxed initiation pausing of ribosomes drives oncogenic translation
- Author
-
Ji Wan, Jun Zhou, Leiming Dong, Xiao-Min Liu, Yuanhui Mao, Aidong Zhou, and Shu-Bing Qian
- Subjects
Carcinogenesis ,Codon, Initiator ,Biology ,medicine.disease_cause ,Biochemistry ,Ribosome ,Malignant transformation ,03 medical and health sciences ,0302 clinical medicine ,Eukaryotic translation ,Start codon ,Genetics ,medicine ,Humans ,RNA, Messenger ,Research Articles ,030304 developmental biology ,0303 health sciences ,Messenger RNA ,Multidisciplinary ,Proteins ,SciAdv r-articles ,Translation (biology) ,Cell biology ,030220 oncology & carcinogenesis ,MRNA methylation ,Ribosomes ,Research Article - Abstract
Ribosome pausing at start codons limits translational output, which is controlled by altered mRNA methylation in cancer cells., Translation is a crucial process in cancer development and progression. Many oncogenic signaling pathways target the translation initiation stage to satisfy the increased anabolic demands of cancer cells. Using quantitative profiling of initiating ribosomes, we found that ribosomal pausing at the start codon serves as a “brake” to restrain the translational output. In response to oncogenic RAS signaling, the initiation pausing relaxes and contributes to the increased translational flux. Intriguingly, messenger RNA (mRNA) m6A modification in the vicinity of start codons influences the behavior of initiating ribosomes. Under oncogenic RAS signaling, the reduced mRNA methylation leads to relaxed initiation pausing, thereby promoting malignant transformation and tumor growth. Restored initiation pausing by inhibiting m6A demethylases suppresses RAS-mediated oncogenic translation and subsequent tumorigenesis. Our findings unveil a paradigm of translational control that is co-opted by RAS mutant cancer cells to drive malignant phenotypes.
- Published
- 2021
- Full Text
- View/download PDF